InvestSMART

Neurotech International Limited (ASX:NTI)

ALERT: Price-sensitive ASX Announcement for NTI
Current share price for NTI : $0.014 -0.002 (-12.50%)+
Announcement
Release
31 Jul 2026 10:59AM
Price at Release
$0.016
Full Release
download
Summary
Neurotech International Limited, a clinical-stage biopharmaceutical company, released its Quarterly Activities Report and Appendix 4C Cash Flow Report for the quarter ending 30 June 2026. The company focused on the development of its NTI164 drug, targeting autism spectrum disorder, with significant activities in clinical operations and regulatory preparations. The quarter saw operating cash outflows of approximately $1.9 million, with cash and equivalents of $2.4 million at the end. Neurotech also secured $3.15 million from a loan against anticipated R&D tax incentives and received FDA clearance for NTI164's IND submission. The company is progressing its Phase 3 trial and expanding its NTI164 Authorised Prescriber Program, while maintaining engagement with regulatory bodies and progressing patent applications in the US.
Key Points
  • Neurotech focuses on NTI164 development for autism spectrum disorder.
  • Quarterly cash outflows were approximately $1.9 million.
  • The company had $2.4 million in cash at quarter-end.
  • Secured $3.15 million from a loan against R&D tax incentives.
  • Received FDA IND clearance for NTI164.
  • Progressing Phase 3 trial and expanding NTI164 Authorised Prescriber Program.
  • Engaging with regulatory bodies and progressing US patent applications.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.